HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GBP510 vaccine

SARS-CoV-2 recombinant protein nanoparticle vaccine

Also Known As:

GBP510 adjuvanted with AS03; GBP510 adjuvanted with Alum; GBP510 adjuvanted with aluminum hydroxide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        GBP510 vaccine: 1

Related Diseases

1.	Myalgia 09/01/2022 - "Fatigue and myalgia were two most frequently reported systemic AEs and more frequently reported in GBP510 adjuvanted with AS03 recipients (79·2% and 78·2% in group 1; 75·0% and 79·8% in group 3, respectively) than in the unadjuvanted vaccine recipients (40·0% and of 40·0% in group 2; 60·8% and 47·1% in group 4) after any vaccination. "
2.	Fatigue 09/01/2022 - "Fatigue and myalgia were two most frequently reported systemic AEs and more frequently reported in GBP510 adjuvanted with AS03 recipients (79·2% and 78·2% in group 1; 75·0% and 79·8% in group 3, respectively) than in the unadjuvanted vaccine recipients (40·0% and of 40·0% in group 2; 60·8% and 47·1% in group 4) after any vaccination. "

Related Drugs and Biologics

1.	Vaccines